Chembio diagnostics evaluates monkeypox rapid point-of-care test development

Hauppauge, n.y., aug. 16, 2022 (globe newswire) -- chembio diagnostics, inc. (chembio) (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox rapid point-of-care (poc) test. chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, dpp, sure check, and stat pak, along with funding partners and the broader market opportunity.
CEMI Ratings Summary
CEMI Quant Ranking